HUP0101160A2 - Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására - Google Patents

Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására

Info

Publication number
HUP0101160A2
HUP0101160A2 HU0101160A HUP0101160A HUP0101160A2 HU P0101160 A2 HUP0101160 A2 HU P0101160A2 HU 0101160 A HU0101160 A HU 0101160A HU P0101160 A HUP0101160 A HU P0101160A HU P0101160 A2 HUP0101160 A2 HU P0101160A2
Authority
HU
Hungary
Prior art keywords
chain
tissue factor
antibody
humanized antibody
human tissue
Prior art date
Application number
HU0101160A
Other languages
English (en)
Inventor
Hideki Adachi
Koh Sato
Naohiro Yabuta
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HUP0101160A2 publication Critical patent/HUP0101160A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgyát humán/egér kiméraantitest képezi, amely humánszöveti faktor (TF) elleni egéreredetű monoklonális antitestvariábilis (V) régióját és humán antitest konstans (C) régiójáttartalmazza. A találmány tárgyát képezi továbbá egy humanizáltantitest, amely humán antitestbe átültetve humán szöveti faktor elleniegéreredetű monoklonális antitest könnyű lánca (L-lánc) variábilisrégiójának és ugyanezen antitest nehéz lánca (H-lánc) variábilisrégiójának (V-régió) komplementaritást meghatározó régióit (CDR)tartalmazza. A találmány tárgyához tartozik továbbá az említettantitest L-lánca és H-lánca; az L-lánc és a H-lánc részét képező V-régió-fragmens, továbbá eljárás a humán szöveti faktor ellenihumanizált antitest előállítására. A találmány tárgyát képezi továbbáa találmány szerinti antitesteket kódoló DNS-molekulák, a találmányszerinti DNS-t hordozó rekombináns vektorok, és a találmány szerintivektorokkal transzformált gazdasejtek. A találmány tárgyát képezitovábbá egy eljárás humán szöveti faktor elleni kiméraantitest éshumanizált antitest előállítására. Szintén a találmány tárgyáhoztartozik egy gyógyászati készítmény és egy terápiás hatóanyagdisszeminált intravaszkuláris koagulációs (DIC) tünetegyütteskezelésére, amely aktív összetevőként humán szöveti faktor ellenihumanizált antitestet tartalmaz. Ó
HU0101160A 1998-04-03 1999-04-02 Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására HUP0101160A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9185098 1998-04-03
PCT/JP1999/001768 WO1999051743A1 (fr) 1998-04-03 1999-04-02 Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises

Publications (1)

Publication Number Publication Date
HUP0101160A2 true HUP0101160A2 (hu) 2001-08-28

Family

ID=14038058

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101160A HUP0101160A2 (hu) 1998-04-03 1999-04-02 Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására

Country Status (19)

Country Link
US (2) US6677436B1 (hu)
EP (2) EP2363484A3 (hu)
JP (2) JP3998419B2 (hu)
KR (1) KR20010042435A (hu)
CN (1) CN1303431A (hu)
AT (1) ATE512225T1 (hu)
AU (1) AU752730B2 (hu)
BR (1) BR9909382A (hu)
CA (1) CA2325346A1 (hu)
DK (1) DK1069185T3 (hu)
ES (1) ES2364266T3 (hu)
HU (1) HUP0101160A2 (hu)
IL (1) IL138801A0 (hu)
NO (1) NO20004946L (hu)
PL (1) PL343322A1 (hu)
PT (1) PT1069185E (hu)
SK (1) SK14812000A3 (hu)
TR (2) TR200002885T2 (hu)
WO (1) WO1999051743A1 (hu)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223491C (en) 1995-06-07 2010-08-10 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US6703197B1 (en) * 1996-11-27 2004-03-09 Martinex R&D, Inc. Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US7764130B2 (en) * 1999-01-22 2010-07-27 Multigig Inc. Electronic circuitry
KR20030008205A (ko) * 1999-10-01 2003-01-24 추가이 세이야쿠 가부시키가이샤 혈액응고 관련 질환의 예방 및 치료
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
EP1263960A2 (en) * 2000-03-16 2002-12-11 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
JPWO2002078738A1 (ja) * 2001-03-26 2004-10-07 鈴木　宏治 血液レオロジー改善剤
JP4342941B2 (ja) * 2001-08-29 2009-10-14 中外製薬株式会社 抗体含有安定化製剤
CZ2004454A3 (cs) * 2001-10-02 2004-09-15 Novo Nordisk A/S Protilátky lidského tkáňového faktoru
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
EP1464702A4 (en) 2001-12-28 2005-09-21 Chugai Pharmaceutical Co Ltd METHOD FOR PROTEIN STABILIZATION
RU2345789C2 (ru) * 2002-05-01 2009-02-10 Шеринг Акциенгезельшафт Новые антитела к тканевому фактору в качестве антикоагулянтов
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
US20060233786A1 (en) * 2002-05-23 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd METHOD FOR STABILIZING PROTEIN PREPARATION
DK2261230T3 (en) 2002-09-11 2017-06-12 Chugai Pharmaceutical Co Ltd Method of Protein Purification.
WO2004039842A2 (en) * 2002-10-31 2004-05-13 Novo Nordisk A/S Humanized tissue factor antibodies
EP1608684A2 (en) * 2003-02-07 2005-12-28 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
KR20060035608A (ko) * 2003-05-30 2006-04-26 센토코 인코포레이티드 항 조직 인자 항체로 종양 성장을 저해하는 방법
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
JP5114055B2 (ja) * 2003-06-19 2013-01-09 ジェネンテック， インク． 障害に関連する凝固の治療用組成物および方法
JP2007504167A (ja) * 2003-08-29 2007-03-01 セントカー・インコーポレーテツド 抗組織因子抗体を用いる移植片の生存を向上する方法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
SG10202008722QA (en) * 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
DE602005026219D1 (de) 2004-10-01 2011-03-17 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
TW200720439A (en) * 2005-03-25 2007-06-01 Glycart Biotechnology Ag Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
PL1876236T3 (pl) 2005-04-08 2015-01-30 Chugai Pharmaceutical Co Ltd Przeciwciała zastępujące czynność czynnika krzepnięcia VIII
CA2605781A1 (en) * 2005-05-09 2007-04-12 Glycart Biotechnology Ag Antigen binding molecules having modified fc regions and altered binding to fc receptors
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
AR055137A1 (es) * 2005-08-26 2007-08-08 Glycart Biotechnology Ag Moleculas de union al antigeno modificadas con actividad de senalizacion celular alterada
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
AU2007353317B2 (en) * 2006-11-15 2012-09-06 Eli Lilly And Company Methods and compositions for treating influenza
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
ES2699273T3 (es) 2006-12-01 2019-02-08 Novartis Ag Anticuerpos anti-P-selectina y métodos de uso de los mismos para tratar enfermedades inflamatorias
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
CN101939424B (zh) 2007-12-05 2016-12-28 中外制药株式会社 抗nr10抗体及其应用
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
PT2271670E (pt) * 2008-03-14 2014-11-28 Allergan Inc Ensaio imunobaseado da atividade do serotipo a da toxina botulínica
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
BRPI0910509B8 (pt) 2008-07-10 2021-05-25 Toray Industries uso do anticorpo, anticorpo e composição farmacêutica
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US8975378B2 (en) 2008-12-25 2015-03-10 Osaka University Human anti-human influenza virus antibody
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
TW201041595A (en) 2009-05-15 2010-12-01 Chugai Pharmaceutical Co Ltd Anti-axl antibody
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
CN101717447B (zh) * 2009-12-17 2012-06-27 山西省生物研究所 一种抗人重组组织因子单克隆抗体的制备方法
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
JP5906739B2 (ja) 2010-02-04 2016-04-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5742713B2 (ja) 2010-02-04 2015-07-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
MX340014B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2011096519A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
BR112013012213A2 (pt) 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
KR20200103845A (ko) 2011-02-25 2020-09-02 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
PL2740798T3 (pl) 2011-08-04 2017-07-31 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworom
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE039219T2 (hu) 2011-08-04 2018-12-28 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
BR112014004828B8 (pt) 2011-09-01 2022-03-29 Chugai Pharmaceutical Co Ltd Métodos para preparação de composições compreendendo anticorpos ou proteínas concentradas por ultrafiltração
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9573993B2 (en) 2012-02-21 2017-02-21 Toray Industries, Inc. Pharmaceutical composition for treatment of cancer comprising an anti-CAPRIN-1 peptide antibody
JP6187255B2 (ja) 2012-02-21 2017-08-30 東レ株式会社 癌の治療及び／又は予防用医薬組成物
PT2818481T (pt) 2012-02-21 2019-10-25 Toray Industries Composição farmacêutica para tratamento e/ou prevenção de cancro
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
CA2869120C (en) 2012-03-30 2023-05-23 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
KR102052400B1 (ko) 2012-03-30 2019-12-06 도레이 카부시키가이샤 담낭암의 치료 및/또는 예방용 의약 조성물
MX362456B (es) 2012-08-24 2019-01-18 Univ California Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CA2886326C (en) 2012-09-28 2021-11-02 Chugai Seiyaku Kabushiki Kaisha Method for evaluating blood coagulation reaction
PL3031826T3 (pl) 2013-08-09 2019-03-29 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
US10538591B2 (en) 2014-03-10 2020-01-21 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
JP6858559B2 (ja) 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016065329A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SI3233921T1 (sl) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Protitelesa proti C5 in postopki za uporabo
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
PL3263132T3 (pl) 2015-02-27 2024-04-15 Chugai Seiyaku Kabushiki Kaisha Kompozycja do leczenia chorób związanych z il-6
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
AU2016248817A1 (en) 2015-04-17 2017-08-17 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
EP3374399A1 (en) 2015-11-11 2018-09-19 Opi Vi- IP Holdco LLC Composition and methods for anti-tnfr2 antibodies
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
SG11201807936VA (en) 2016-03-14 2018-10-30 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
MX2018011109A (es) 2016-03-28 2018-11-09 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
CA3035327A1 (en) 2016-09-06 2018-03-15 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
WO2018079740A1 (ja) 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
WO2018199214A1 (ja) 2017-04-27 2018-11-01 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
TW201922796A (zh) 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
CN111727075B (zh) * 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
BR112020013679A2 (pt) 2018-01-04 2020-12-01 Iconic Therapeutics, Inc. anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados
AU2019242520A1 (en) 2018-03-30 2020-10-29 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
CN115649558A (zh) 2018-05-28 2023-01-31 中外制药株式会社 填充喷嘴
AU2020258025A1 (en) 2019-04-18 2021-11-25 Ac Immune Sa Novel molecules for therapy and diagnosis
CN115151562A (zh) 2019-12-04 2022-10-04 Ac免疫有限公司 用于治疗和诊断的新分子
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JPWO2021182570A1 (hu) 2020-03-12 2021-09-16
US20230159635A1 (en) 2020-03-12 2023-05-25 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20220152309A (ko) 2020-03-12 2022-11-15 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
US20230140155A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
CN115397860A (zh) 2020-05-14 2022-11-25 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
US20230183376A1 (en) 2020-05-22 2023-06-15 Chugai Seiyaku Kabushiki Kaisha Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
US20240100187A1 (en) 2020-12-18 2024-03-28 Ac Immune Sa Antibody Delivery
JPWO2022270524A1 (hu) 2021-06-23 2022-12-29
AU2022296193A1 (en) 2021-06-23 2024-01-18 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022320304A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4378476A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4378477A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20240051956A (ko) 2021-09-03 2024-04-22 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CA3233924A1 (en) 2021-10-08 2023-04-13 Kengo ARAI Method for preparing prefilled syringe formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
DK0628639T3 (da) 1991-04-25 2000-01-24 Chugai Pharmaceutical Co Ltd Rekonstitueret humant antistof mod human interleukin-6-receptor
WO1994005328A1 (en) 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2223491C (en) 1995-06-07 2010-08-10 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN1303431A (zh) 2001-07-11
KR20010042435A (ko) 2001-05-25
TR200002885T2 (tr) 2000-12-21
PT1069185E (pt) 2011-08-11
CA2325346A1 (en) 1999-10-14
AU3055699A (en) 1999-10-25
SK14812000A3 (sk) 2001-08-06
NO20004946L (no) 2000-12-04
DK1069185T3 (da) 2011-06-27
PL343322A1 (en) 2001-08-13
JP3998419B2 (ja) 2007-10-24
EP1069185A1 (en) 2001-01-17
US7494647B2 (en) 2009-02-24
EP2363484A3 (en) 2012-04-25
NO20004946D0 (no) 2000-10-02
JP4180106B2 (ja) 2008-11-12
TR200101541T2 (tr) 2002-06-21
AU752730B2 (en) 2002-09-26
BR9909382A (pt) 2000-12-05
EP1069185A4 (en) 2005-01-19
WO1999051743A1 (fr) 1999-10-14
IL138801A0 (en) 2001-10-31
US20040044187A1 (en) 2004-03-04
EP2363484A2 (en) 2011-09-07
JP2008161198A (ja) 2008-07-17
EP1069185B1 (en) 2011-06-08
ATE512225T1 (de) 2011-06-15
ES2364266T3 (es) 2011-08-30
US6677436B1 (en) 2004-01-13

Similar Documents

Publication Publication Date Title
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
CA2223491A1 (en) Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US7491514B2 (en) Reducing the immunogenicity of anti-CD20 antibodies by framework patching
CN105968206B (zh) 抗erbb3抗体
ES2537278T3 (es) Agentes de unión a esclerostina
RU2524136C2 (ru) Моноклональные антитела против белка rgm а и их применение
PE20030846A1 (es) Anticuerpos para cd40
RU96115107A (ru) "очеловеченные" антитела и их использование
CN110407941A (zh) Cd39的高亲和力抗体及其用途
ATE188874T1 (de) Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen
CA2189015A1 (en) Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
CN104245736B (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
RU2013152730A (ru) Антитела к ох-2/cd200 и их применение
AU2003220525A1 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
RU2006123481A (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
WO2006055809A3 (en) Antibodies against vascular endothelial growth factor receptor-1
EA200301098A1 (ru) Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
ITFI930246A1 (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
JP2024016024A5 (hu)
RU2010119450A (ru) Антитело против bst2
RU2008138541A (ru) Способы разрушения клеток с использованием эффекторных функций анти-epha4 антител
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
Hale Therapeutic antibodies—Delivering the promise?
Winter Antibody engineering